Researchers develop new methods for targeted cancer gene and cell treatment

Scientists have introduced two distinct experimental approaches aimed at improving the precision of cancer treatments.

In the United States, researchers led by Dr. David Rusling have developed a method using synthetic DNA molecules to target cancer-linked genes directly. By utilizing triplex-forming oligonucleotides (TFOs) and a synthetic DNA base known as Z, the team successfully addressed the challenge of binding to double-stranded DNA. This technique allows for the targeting of specific, difficult-to-reach GC-rich regions of the genome, potentially offering a highly efficient way to control gene activity at its source.

Separately, researchers at the RIKEN Pioneering Research Institute in Japan are investigating a method to turn cancer cells against themselves. Led by Katsunori Tanaka, the team is testing a compound that uses carbon monoxide, which is naturally produced by many cancer cells, to manufacture anticancer drugs directly inside the malignant cells. This approach aims to minimize the systemic toxicity and side effects typically associated with conventional chemotherapy by ensuring the therapeutic agents are only activated within the tumor environment.